AU2002351456A1 - Method and composition for preventing or reducing the symptoms of insulin resistance syndrome - Google Patents
Method and composition for preventing or reducing the symptoms of insulin resistance syndromeInfo
- Publication number
- AU2002351456A1 AU2002351456A1 AU2002351456A AU2002351456A AU2002351456A1 AU 2002351456 A1 AU2002351456 A1 AU 2002351456A1 AU 2002351456 A AU2002351456 A AU 2002351456A AU 2002351456 A AU2002351456 A AU 2002351456A AU 2002351456 A1 AU2002351456 A1 AU 2002351456A1
- Authority
- AU
- Australia
- Prior art keywords
- composition
- chromium
- amount
- niacin
- symptoms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims description 54
- 238000000034 method Methods 0.000 title claims description 26
- 208000024891 symptom Diseases 0.000 title claims description 18
- 208000031773 Insulin resistance syndrome Diseases 0.000 title description 5
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 50
- 239000011651 chromium Substances 0.000 claims description 50
- 229910052804 chromium Inorganic materials 0.000 claims description 50
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 27
- 239000011664 nicotinic acid Substances 0.000 claims description 27
- 229960003512 nicotinic acid Drugs 0.000 claims description 27
- 235000001968 nicotinic acid Nutrition 0.000 claims description 27
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 14
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 12
- 206010022489 Insulin Resistance Diseases 0.000 claims description 10
- ZMJBYMUCKBYSCP-UHFFFAOYSA-N (+)-Erythro-hydroxycitric acid Natural products OC(=O)C(O)C(O)(C(O)=O)CC(O)=O ZMJBYMUCKBYSCP-UHFFFAOYSA-N 0.000 claims description 9
- ZMJBYMUCKBYSCP-AWFVSMACSA-N (1s,2r)-1,2-dihydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)[C@@H](O)[C@@](O)(C(O)=O)CC(O)=O ZMJBYMUCKBYSCP-AWFVSMACSA-N 0.000 claims description 9
- JDLKFOPOAOFWQN-VIFPVBQESA-N Allicin Natural products C=CCS[S@](=O)CC=C JDLKFOPOAOFWQN-VIFPVBQESA-N 0.000 claims description 9
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 9
- JDLKFOPOAOFWQN-UHFFFAOYSA-N allicin Chemical compound C=CCSS(=O)CC=C JDLKFOPOAOFWQN-UHFFFAOYSA-N 0.000 claims description 9
- 235000010081 allicin Nutrition 0.000 claims description 9
- 229930183009 gymnemic acid Natural products 0.000 claims description 9
- 229930182490 saponin Natural products 0.000 claims description 9
- 150000007949 saponins Chemical class 0.000 claims description 9
- 235000017709 saponins Nutrition 0.000 claims description 9
- 239000011669 selenium Substances 0.000 claims description 9
- 229910052711 selenium Inorganic materials 0.000 claims description 9
- 239000011701 zinc Substances 0.000 claims description 9
- 229910052725 zinc Inorganic materials 0.000 claims description 9
- 229930014669 anthocyanidin Natural products 0.000 claims description 7
- 235000008758 anthocyanidins Nutrition 0.000 claims description 7
- NWKFECICNXDNOQ-UHFFFAOYSA-N flavylium Chemical compound C1=CC=CC=C1C1=CC=C(C=CC=C2)C2=[O+]1 NWKFECICNXDNOQ-UHFFFAOYSA-N 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 6
- 229940016667 resveratrol Drugs 0.000 claims description 6
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims description 3
- 235000018991 trans-resveratrol Nutrition 0.000 claims description 3
- -1 trarø-resveratrol Natural products 0.000 claims description 3
- 235000011649 selenium Nutrition 0.000 claims description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 36
- 208000011580 syndromic disease Diseases 0.000 description 22
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 20
- 102000004877 Insulin Human genes 0.000 description 18
- 108090001061 Insulin Proteins 0.000 description 18
- 229940125396 insulin Drugs 0.000 description 18
- 208000008589 Obesity Diseases 0.000 description 13
- 235000020824 obesity Nutrition 0.000 description 13
- 206010020772 Hypertension Diseases 0.000 description 12
- 206010012601 diabetes mellitus Diseases 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 235000012000 cholesterol Nutrition 0.000 description 5
- 201000008980 hyperinsulinism Diseases 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 208000002705 Glucose Intolerance Diseases 0.000 description 4
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 4
- 230000000923 atherogenic effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 3
- 108010010234 HDL Lipoproteins Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000009142 chromium supplementation Methods 0.000 description 3
- HPCCGRCEBFBZQP-UHFFFAOYSA-N chromium;pyridine-3-carboxylic acid Chemical compound [Cr].OC(=O)C1=CC=CN=C1 HPCCGRCEBFBZQP-UHFFFAOYSA-N 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000003859 lipid peroxidation Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000002417 nutraceutical Substances 0.000 description 3
- 235000021436 nutraceutical agent Nutrition 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 238000004260 weight control Methods 0.000 description 3
- 230000004584 weight gain Effects 0.000 description 3
- 235000019786 weight gain Nutrition 0.000 description 3
- 208000004611 Abdominal Obesity Diseases 0.000 description 2
- 206010065941 Central obesity Diseases 0.000 description 2
- 244000078534 Vaccinium myrtillus Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 235000002532 grape seed extract Nutrition 0.000 description 2
- 239000005555 hypertensive agent Substances 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 229940110280 zinc methionine Drugs 0.000 description 2
- CNMFGFBWPBBGKX-SCGRZTRASA-L zinc;(2s)-2-amino-4-methylsulfanylbutanoate Chemical compound [Zn+2].CSCC[C@H](N)C([O-])=O.CSCC[C@H](N)C([O-])=O CNMFGFBWPBBGKX-SCGRZTRASA-L 0.000 description 2
- 102000005606 Activins Human genes 0.000 description 1
- 108010059616 Activins Proteins 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 244000303965 Cyamopsis psoralioides Species 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 206010014486 Elevated triglycerides Diseases 0.000 description 1
- 208000007530 Essential hypertension Diseases 0.000 description 1
- 206010056465 Food craving Diseases 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
- 239000009140 Grape Seed Proanthocyanidin Substances 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 1
- 102100022119 Lipoprotein lipase Human genes 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 244000250129 Trigonella foenum graecum Species 0.000 description 1
- 235000001484 Trigonella foenum graecum Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000488 activin Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000036523 atherogenesis Effects 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 235000019209 bilberry extract Nutrition 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 235000019216 blueberry extract Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 229940046374 chromium picolinate Drugs 0.000 description 1
- 229940060736 chromium polynicotinate Drugs 0.000 description 1
- GJYSUGXFENSLOO-UHFFFAOYSA-N chromium;pyridine-2-carboxylic acid Chemical compound [Cr].OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1 GJYSUGXFENSLOO-UHFFFAOYSA-N 0.000 description 1
- 229920002770 condensed tannin Polymers 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 230000014101 glucose homeostasis Effects 0.000 description 1
- 229940087603 grape seed extract Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 108010042209 insulin receptor tyrosine kinase Proteins 0.000 description 1
- 230000006372 lipid accumulation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000036513 peripheral conductance Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000276 sedentary effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 235000001019 trigonella foenum-graecum Nutrition 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 239000001717 vitis vinifera seed extract Substances 0.000 description 1
Description
METHOD AND COMPOSITION FOR PREVENTING OR REDUCING THE SYMPTOMS OF INSULIN RESISTANCE SYNDROME
BACKGROUND OF THE INVENTION
The present invention relates generally to a method and composition for preventing or reducing the symptoms of insulin resistance syndrome in a person.
An insulin resistance syndrome that has been identified as "Syndrome X" by previous research is a common metabolic disorder affecting more than 75 million Americans to some degree. Insulin resistance is a condition in which the body becomes resistant to its own insulin. The body of the person affected compensates by releasing more insulin, elevating body insulin levels. This elevated insulin level leads to increased risk of a variety of symptoms, including diabetes, obesity, and heart disease.
Syndrome X appears to be highly prevalent in the obese, individual elements of Syndrome X (obesity, hypertension, lipid disturbances, and glucose intolerance) are frequently encountered during a typical person's life span, and they tend to be increasing apparent as people age, usually becoming most prevalent after age 35. Theoretical considerations suggest that insulin resistance may be a primary factor that plays a causative role in the induction of both obesity and diabetes. Atherogenic risk factors associated with obesity and Syndrome X contribute independently to the development of atherosclerotic disease, and risk of a cardiovascular event increases sharply with the burden of risk factors associated with obesity.
Animal models of Syndrome X, as observed in rats fed high fat diets, exhibit excess accumulation of muscle triglyceride coincident with development of insulin resistance. This also seems to occur in humans; several studies demonstrate increased muscle triglyceride content in insulin resistant states. There is substantial evidence indicating that excess muscle and liver lipid accumulation causes or exacerbates insulin resistance in Syndrome X and in Type II diabetes. Development of strategies to prevent this, therefore, seem worthwhile.
Avoiding weight gain from adolescence to middle age is known to reduce cardiovascular morbidity and mortality. Despite much debate in the past regarding the influence of obesity on health and the benefits of maintaining normal weight, it is clear that changes in weight correlate to changes in several atherogenic risk factors. Recent perspective studies indicate a continuous graded influence of body mass index (BMI), the ratio of weight expressed in kilograms divide by the height meters squared, on the rate of coronary disease development, increased risk is evident at BMI levels below average, indicating that moderate obesity can be unhealthy. Central obesity, typically including measurements of waist girth or waist to hip ratio, has been shown to be more metabolically disadvantageous than other forms of obesity and, as a consequence, it is considered a strong predictor of cardiovascular disease.
The mechanism whereby obesity and weight gain promote atherogenic risk factors and, in turn, cardiovascular disease is well established. Excess body fat has been shown to increase resistance to insulin action and reduce uptake of glucose by peripheral tissues. Abdominal obesity, in particular, is associated with insulin resistance, hyperinsulinemia, a relative deficiency of lipoprotein lipase, elevated triglycerides, reduced HDL-cholesterol and small dense LDL-particles. Obesity may promote increased absorption in the renal tubules, expanding blood volume and inducing an autonomic imbalance that results in hypertension. In addition, insulin
resistance often eventuates into glucose intolerance and diabetes which in turn accelerates atherogenesis.
Obesity is clearly the most prevalent metabolic disorder in the United States, and weight control deserves a high priority to curb cardiovascular disease and the associated predisposing conditions, such as lipidemia, hypertension and glucose intolerance. The benefits of weight control on the major atherogenic risk factors and the insulin resistance syndrome should provide a strong incentive and rationale for control of obesity. There is no other risk factor that affects the cardiovascular risk profile as strongly. It is well known that non-insulin dependent type II diabetes is highly associated with obesity. It has been reported that healthy persons with elevated insulin levels have increased levels of LDL cholesterol, decreased HDL cholesterol and high blood pressure compared with healthy individuals who have normal insulin levels. Diabetes is associated with high blood lipids, hypertension and a tendency of blood platelets to clot, which can block arteries resulting in heart attack or stroke. Diabetes causes a defect in glucose homeostasis. Weight control is a logical first approach to avoid moderate degrees of hypertension, dyslipidemia, glucose tolerance and hyperinsulinemia that constitute Syndrome X.
To overcome glucose tolerance, patients with syndrome X secrete large amounts of insulin. Treatment of Syndrome X should therefore be aimed at: 1) increasing insulin sensitivity; 2) attenuating day-long hyperinsulinemia; and 3) pharmacologic treatment of the specific manifestations of syndrome X, if lifestyle interventions such as weight loss are not entirely successful. The two major lifestyle modulators of insulin action are body weight and physical fitness; the heavier and the more sedentary a patient is, the greater the degree of insulin resistance and compensatory hyperinsulinemia.
However, even with control of weight, many people can still develop Syndrome X. Also, many people find controlling their weight to be difficult, and they are unsuccessful in their attempts. Therefore, pharmocological treatments are needed to help reduce the effects of Syndrome X in persons.
Chromium helps insulin metabolize fat, turn protein into muscle and convert sugar into energy. It is an essential trace element required for normal protein, fat and carbohydrate metabolism. Chromium levels are known to decrease with age, and marginal chromium deficiencies appear to be widespread. Chromium is important for energy production and plays a role in regulating appetite, reducing sugar cravings, and increasing lean body mass.
Niacin-bound chromium (also called chromium nicotinate or chromium polynicotinate) dramatically increases the effectiveness of chromium in a person ingesting it. Normally, chromium is poorly absorbed and utilized by the body. However, researchers have found that the most potent form of chromium in nature is that form bound to the B-vitamin, niacin. Furthermore, previous research discoveries led to the identification of Glucose Tolerance Factor or "GTF", a biologically active form of chromium that facilitates normal insulin function, which is responsible for normal glucose (blood sugar) metabolism. Researchers have found that a particular oxygen-coordinated chromium niacin complex is the most potent form of all, being over eighteen times more potent than the next closest form of niacin-bound chromium tested.
In 1997, researchers at the University of Texas, Austin, showed that a combination of administration of niacin-bound chromium along with exercise in obese women resulted in a significant weight loss in the women and also lowered the increase in insulin levels when the women were orally fed glucose. In contrast, those
taking chromium picolinate, a different form of chromium, were found to show significant weight gain. In 1999, researchers at Georgetown University Medical Center showed that compared to a placebo, niacin-bound chromium caused significant loss of body fat and sparing of muscle (lean body mass) in overweight African- American women. Also, tests on the blood chemistries of the women revealed no significant adverse effects from the ingestion of 600 μg of elemental chromium daily for 2 months. This observation demonstrated the safety of administration of niacin-bound chromium at the tested levels.
In 1994, researchers at Auburn University showed that supplementation with 200 megs of niacin-bound chromium significantly lowered moderate levels of cholesterol by an average of 14 percent and improved the ratio of total cholesterol to HDL ("good") cholesterol by 7 percent in male athletes. In 1995, researchers at Georgetown University Medical Center showed that a combination of niacin-bound chromium and soluble fiber (i.e., guar) significantly inhibited sugar-induced high blood pressure in rats. In 1997, researchers at Georgetown University Medical Center showed that niacin-bound chromium inhibited sugar-induced high blood pressure, improved long-term blood sugar status and reduced liver and kidney lipid peroxidation in rats. In 2000, researchers at Georgetown University Medical Center showed that a combination of niacin-bound chromium and grape seed proanthocyanidin extract significantly lowered both total cholesterol levels and LDL ("bad") cholesterol levels by 10 and 14 percent, respectively, in people with elevated blood cholesterol levels.
Diabetic patients have been found to have lower serum chromium levels and a higher chromium excretion rate. Treatment with niacin-bound chromium has been found to improve glucose tolerance in diabetic patients. Dietary trivalent chromium has been shown to have significant beneficial effects on the insulin system.
It has been demonstrated that essential hypertension may be due to insulin perturbations. As high dose chromium supplementation seems nontoxic, chromium may prove to be a useful means to lower blood pressure in some essential hypertensives as well as diabetic hypertensives. It also has been shown that chromium supplementation may prove to be the most useful means to prevent or treat type II diabetes mellitus and related cardiovascular disorders. Chromium supplementation amplifies insulin receptor tyrosine kinase activity, which explains the relationship between chromium and its effects in diabetes. Chromium further reduces vascular smooth muscle calcium loads and thus reduces peripheral vascular resistance in insulin-resistant states.
Recently, the U.S. Department of Agriculture (USDA) found that many middle-age diabetics could overcome their symptoms by taking a chromium supplement. The USDA's findings suggest that very low chromium intakes may be putting millions of Americans on the road to diabetes (and high blood cholesterol) and that the process could be reversed by supplementing with chromium. A separate study found that marginal chromium loss in male athletes resulting in impaired insulin function can be improved by supplementation with niacin-bound chromium.
However, though the above studies demonstrate that acm inistering niacin-bound chromium may serve as a beneficial therapeutic method for reducing or preventing the various symptoms associated with Syndrome X, this has not been entirely effective. Improved methods and compositions, therefore, are necessary to provide for preventing or and reducing the symptoms of Syndrome X in persons. The present invention fulfills this need and provides for further advantages.
SUMMARY OF THE INVENTION
The present invention resides in a method for preventing or reducing the symptoms of insulin resistance in a person, the method comprising: identifying a person suffering from or at risk for suffering from the symptoms; and a< ιinistering a composition comprising an effective amount of niacin-bound chromium that, when administered to the person, alleviates the symptoms. The method preferably incorporates administering a composition comprising between about 50 and about 1,000 μg niacin-bound chromium, preferably in two doses per day.
In a preferred aspect of the method, the composition incorporates three compounds selected from the following group: (-) hydroxycitric acid, zinc, trans- resveratrol, gymnemic acid, selenium, anthocyanidinc, allicin, or saponins.
Preferably, if present, the amount of (-)hydroxycitric acid in the composition is between about 250 and about 2,500 mg, the amount of zinc in the composition is between about 5 and about 50 mg, the amount of trøws-resveratrol in the composition is between about 5 and about 50 mg, the amount of gymnemic acid in the composition is between about 50 and about 200 mg, the amount of selenium in the composition is between about 0.025 mg and about 0.1 mg, the amount of anthocyanidins in the composition is between about 5 and about 50 mg, the amount of allicin in the composition is between about 2 and about 8 mg, and the amount of saponins in the composition is between about 100 and about 300 mg.
The present invention also resides in a composition comprising niacin- bound chromium and three compounds selected from the group consisting of (-) hydroxycitric acid, zinc, tra«5-resveratrol, gymnemic acid, selenium, anthocyanidins, allicin, and saponins. Preferred compositions include amounts of these compounds in the above-referenced amounts.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
The present invention resides in a method for preventing or reducing the symptoms of Syndrome X in a person, incorporating a step of identifying a person having the Syndrome, and then administering an amount of niacin-bound chromium to the person sufficient to prevent or reduce the symptoms of the Syndrome. The present invention also resides in compositions incorporating niacin-bound chromium that, when ingested in sufficient quantity by a person, prevent or reduce the symptoms of Syndrome X in the person.
The method of the present invention involves first identifying a person having Syndrome X. A diagnosis of Syndrome X is made based on observing some or all of the following common symptoms: impaired glucose tolerance, hyperinsulinemia, diabetes, hypertriglyceridemia, elevated LD cholesterol, low HDL cholesterol, hypertension, diabetes, and hypertension. Then, the person is administered an effective amount of niacin-bound chromium, on a daily basis. Preferably, the amount of niacin-bound chromium administered to an adult ranges from about 100 to about 1000 micrograms per day, taken in two daily doses. The niacin-bound chromium preferably is administered orally in a variety of forms, including capsule, tablet, beverage, food additive, powder, liquid, or food.
Preferred aspects of the method of the present invention involve adrninistration of additional compounds along with the niacin-bound chromium, including: one or more of the following: (-)hydroxycitric acid; zinc, preferably from zinc methionine; trøws-resveratrol; gymnemic acid; selenium; anthocyanidins, preferably from bilberry, blueberry, or grape seed extracts; allicin, preferably from garlic; and saponins, preferably from fenugreek. These components work synergistically with the niacin-bound chromium to improve its function in alleviating
the symptoms of Syndrome X. Particularly preferred compositions administered include any three of the components in the following amounts: 50 to 1000 μg niacin- bound chromium; 250 to 2500 mg (-)hydroxycitric acid; 5 to 50 mg zinc; 1 to 5 mg trøra-resveratrol; 50 to 200 mg gymnemic acid; 0.025 to 0.1 mg selenium; 5 to 50 mg anthocyanidins; 2 to 8 mg allicin; and 100 to 300 mg saponins.
EXAMPLE
Studies were conducted to evaluate the efficacy of a combination of natural products, including niacin-bound chromium, on lowering high blood pressure, one of the particular symptoms commonly associated with Syndrome X. One half of a group of 100 normotensive rats were fed a diet containing the following: chromium nicotinate at a human equivalency dosage of 400 μg of elemental chromium (marketed under the brand name ChromeMate by InterHealth Nutraceuticals of Benicia, California), zinc methionine (marketed under the brand name OptiZinc by InterHealth Nutraceuticals), and grape seed extract incorporating proanthocyanidins (marketed under the brand name ActiVin by InterHealth Nutraceuticals). The rats that were placed on diets containing supplemental chromium nicotinate had significantly lowered blood pressure and lipid peroxidation in their livers and kidneys than rats fed normal diets. Sugar-induced hypertension also was reduced in the rats, along with hepatic and renal lipid peroxidation and glycosylated hemoglobin levels.
Although the invention has been disclosed in detail with reference only to the preferred embodiments, those skilled in the art will appreciate that additional methods and compositions can be made without departing from the scope of the invention.
Claims
1. A method for preventing or reducing the symptoms of insulin resistance in a person, the method comprising: identifying a person suffering from or at risk for suffering from the symptoms; and administering a composition comprising an effective amount of niacin- bound chromium that, when administered to the person, alleviates the symptoms.
2. A method as defined in claim 1, wherein the step of administering an amount of the composition incorporates adrninistering a composition comprising between about 50 and about 1,000 μg niacin-bound chromium.
3. A method as defined in claim 1, wherein the step of adrninistering comprises administering the composition in two doses per day.
4. A method as defined in claim 1, wherein the step of administering an amount of the composition incorporates administering a composition further comprising three compounds selected from the group consisting of (-) hydroxycitric acid, zinc, trarø-resveratrol, gymnemic acid, selenium, anthocyanidinc, allicin, or saponins.
5. A method as defined in claim 4, wherein the amount of (-)hydroxycitric acid in the composition is between about 250 and about 2,500 mg.
6. A method as defined in claim 4, wherein the amount of zinc in the composition is between about 5 and about 50 mg.
7. A method as defined in claim 4, wherein the amount of trans- resveratrol in the composition is between about 5 and about 50 mg.
8. A method as defined in claim 4, wherein the amount of gymnemic acid in the composition is between about 50 and about 200 mg.
9. A method as defined in claim 4, wherein the amount of selenium in the composition is between about 0.025 mg and about 0.1 mg.
10. A method as defined in claim 4, wherein the amount of anthocyanidins in the composition is between about 5 and about 50 mg.
11. A method as defined in claim 4, wherein the amount of allicin in the composition is between about 2 and about 8 mg.
12. A method as defined in claim 4, wherein the amount of saponins in the composition is between about 100 and about 300 mg.
13. A composition comprising niacin-bound chromium and three compounds selected from the group consisting of (-) hydroxycitric acid, zinc, trans- resveratrol, gymnemic acid, selenium, anthocyanidins, allicin, and saponins.
14. A composition as defined in claim 13, wherein the composition comprises between about 50 and about 1,000 μg niacin-bound chromium.
15. A composition as defined in claim 13, wherein the composition comprises between about 250 and about 2,500 mg (-)hydroxycitric acid.
16. A composition as defined in claim 13, wherein the composition comprises between about 5 and about 50 mg zinc.
17. A composition as defined in claim 13, wherein the composition comprises between about 5 and about 50 mg trørø-resveratrol.
18. A composition as defined in claim 13, wherein the composition comprises between about 50 and about 200 mg gymnemic acid.
19. A composition as defined in claim 13, wherein the composition comprises between about 0.025 and about 0.1 mg selenium.
20. A composition as defined in claim 13, wherein the composition comprises between about 5 and about 50 mg anthocyanidins.
21. A composition as defined in claim 13, wherein the composition comprises between about 2 and about 8 mg allicin.
22. A composition as defined in claim 13, wherein the composition comprises between about 100 and about 300 mg saponins in the composition is between about 100 and about 300 mg.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32789601P | 2001-10-05 | 2001-10-05 | |
| US60/327,896 | 2001-10-05 | ||
| PCT/US2002/031987 WO2003039535A1 (en) | 2001-10-05 | 2002-10-07 | Method and composition for preventing or reducing the symptoms of insulin resistance syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2002351456A1 true AU2002351456A1 (en) | 2003-07-24 |
| AU2002351456B2 AU2002351456B2 (en) | 2006-11-30 |
Family
ID=23278548
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002351456A Ceased AU2002351456B2 (en) | 2001-10-05 | 2002-10-07 | Method and composition for preventing or reducing the symptoms of insulin resistance syndrome |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US7119110B2 (en) |
| EP (1) | EP1438038A4 (en) |
| JP (1) | JP2005508371A (en) |
| AU (1) | AU2002351456B2 (en) |
| CA (1) | CA2462158A1 (en) |
| IL (1) | IL161186A0 (en) |
| MX (1) | MXPA04003233A (en) |
| WO (1) | WO2003039535A1 (en) |
| ZA (1) | ZA200402688B (en) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999003464A1 (en) | 1997-07-14 | 1999-01-28 | Interhealth Nutraceuticals Incorporated | Hydroxycitric acid compositions, pharmaceutical and dietary supplements and food products made therefrom, and methods for their use in reducing body weight |
| US20040157929A1 (en) * | 2002-04-01 | 2004-08-12 | Ohia Sunny E. | Method for increasing serotonin levels in a person by administration of a composition incorporating(-)hydroxycitric acid, and related compositions thereof |
| US7119110B2 (en) | 2001-10-05 | 2006-10-10 | Interhealth Nutraceuticals Incorporated | Method and composition for preventing or reducing the symptoms of insulin resistance syndrome |
| US20030119913A1 (en) * | 2001-12-20 | 2003-06-26 | Ohia Sunny E. | Method for increasing serotonin levels in a person by administration of a composition incorporating (-)-hydroxycitric acid, and related compositions thereof |
| JP2005523295A (en) * | 2002-03-01 | 2005-08-04 | ノバガリ、ファルマ、エスアー | Self-emulsifying drug delivery system for poorly soluble drugs |
| US7977049B2 (en) * | 2002-08-09 | 2011-07-12 | President And Fellows Of Harvard College | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
| US20040186181A1 (en) * | 2003-03-21 | 2004-09-23 | Interhealth Nutraceuticals, Incorporated | Method and composition for decreasing ghrelin levels |
| US20060084135A1 (en) * | 2003-07-01 | 2006-04-20 | Howitz Konrad T | Compositions for manipulating the lifespan and stress response of cells and organisms |
| US8017634B2 (en) | 2003-12-29 | 2011-09-13 | President And Fellows Of Harvard College | Compositions for treating obesity and insulin resistance disorders |
| AU2004312072B2 (en) * | 2003-12-29 | 2011-06-23 | President And Fellows Of Harvard College | Compositions for treating or preventing obesity and insulin resistance disorders |
| EP1577320B1 (en) | 2004-03-19 | 2012-07-18 | Institut Pasteur | Peptides derived from human BPLP protein, polynucleotides coding for said peptides and antibodies directed against said peptides |
| US20050215644A1 (en) * | 2004-03-19 | 2005-09-29 | Interhealth Nutraceuticals, Inc. | Methods for increasing neurotransmitter levels using hydroxycitric acid |
| EP2305352A1 (en) | 2004-04-02 | 2011-04-06 | Merck Sharp & Dohme Corp. | 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders |
| AU2005262472B2 (en) * | 2004-06-16 | 2011-10-27 | President And Fellows Of Harvard College | Methods and compositions for modulating bax-mediated apoptosis |
| WO2006001278A1 (en) * | 2004-06-28 | 2006-01-05 | Kao Corporation | Ampk activator |
| JP2006273834A (en) * | 2004-06-28 | 2006-10-12 | Kao Corp | AMPK activator |
| US20060014705A1 (en) * | 2004-06-30 | 2006-01-19 | Howitz Konrad T | Compositions and methods for selectively activating human sirtuins |
| US20060029642A1 (en) | 2004-08-03 | 2006-02-09 | Dusan Miljkovic | Methods and compositions for improved chromium complexes |
| WO2006138418A2 (en) | 2005-06-14 | 2006-12-28 | President And Fellows Of Harvard College | Improvement of cognitive performance with sirtuin activators |
| US20070149466A1 (en) * | 2005-07-07 | 2007-06-28 | Michael Milburn | Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders |
| CA2623418C (en) * | 2005-09-28 | 2015-11-03 | The Regents Of The University Of California | Use of a polyphenol extract of grape for lowering blood pressure in a subject suffering from metabolic syndrome or pre-hypertension |
| US7912716B2 (en) * | 2005-10-06 | 2011-03-22 | Sony Online Entertainment Llc | Generating words and names using N-grams of phonemes |
| JP2007126390A (en) * | 2005-11-02 | 2007-05-24 | Mercian Corp | Blood sugar level lowering agent |
| WO2007143002A2 (en) * | 2006-05-31 | 2007-12-13 | Interhealth Nutraceuticals, Inc. | Nutraceutical treatments for diabetic and non-diabetic wound healing |
| US20100062087A1 (en) * | 2006-06-02 | 2010-03-11 | Interhealth Nutraceuticals, Inc. | Nutraceutical Treatments for Diabetic and Non-Diabetic Wound Healing |
| JP5045879B2 (en) * | 2006-06-07 | 2012-10-10 | 株式会社龍泉堂 | A mixture having an effect of improving insulin resistance, an effect of suppressing weight gain, and an effect of preventing and improving fatty liver |
| TW201002332A (en) * | 2008-07-07 | 2010-01-16 | Univ Nat Chunghsing | Composition for preventing and controlling fatty liver disease |
| EP2348857B1 (en) | 2008-10-22 | 2016-02-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| AU2009309037A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| US20100323031A1 (en) * | 2009-06-22 | 2010-12-23 | Glykon Technologies Group, Llc | Synergistic combination to enhance blood glucose and insulin metabolism |
| JP2013520502A (en) | 2010-02-25 | 2013-06-06 | メルク・シャープ・エンド・ドーム・コーポレイション | Novel cyclic benzimidazole derivatives that are useful anti-diabetic drugs |
| US20130156720A1 (en) | 2010-08-27 | 2013-06-20 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
| JP5728099B2 (en) | 2011-02-25 | 2015-06-03 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | Novel cyclic azabenzimidazole derivatives useful as antidiabetic agents |
| RU2015106909A (en) | 2012-08-02 | 2016-09-27 | Мерк Шарп И Доум Корп. | ANTI-DIABETIC TRICYCLIC COMPOUNDS |
| WO2014130608A1 (en) | 2013-02-22 | 2014-08-28 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| EP2970119B1 (en) | 2013-03-14 | 2021-11-03 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| CN106659215A (en) | 2014-06-12 | 2017-05-10 | 福尔公司 | Sweet taste receptor antagonist compositions |
| CN106491641A (en) * | 2016-10-28 | 2017-03-15 | 乌林奇 | A kind of compsn. consisting of influenza virus surface of targeting preventing and treating cerebral thrombosiss and application |
| EP3551176A4 (en) | 2016-12-06 | 2020-06-24 | Merck Sharp & Dohme Corp. | ANTIDIABETIC HETEROCYCLIC COMPOUNDS |
| WO2018118670A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
| IT201700032960A1 (en) * | 2017-03-24 | 2018-09-24 | Akademy Pharma S R L | NUTRACEUTICAL COMPOUND FOR THE TREATMENT OF THE EXCESS OF WEIGHT AND MODERATE HYPERCOLESTEROLEMIA AND DISGLICEMIA |
| WO2021247289A1 (en) * | 2020-06-02 | 2021-12-09 | Glykon Technologies Group, Llc | Reducing triglyceride levels and cortisol levels with pharmaceutical preparations |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3764692A (en) | 1970-09-30 | 1973-10-09 | Hoffmann La Roche | Method of treating obesity |
| US4923855A (en) | 1983-07-08 | 1990-05-08 | The William Seroy Group | Synthetic GTF chromium material and process therefor |
| US5194615A (en) | 1983-07-08 | 1993-03-16 | The William Seroy Group | Synthetic GTF chromium nicotinate material and its preparation |
| US4954492A (en) * | 1983-07-08 | 1990-09-04 | The William Seroy Group | Synthetic GTF chromium material for decreasing blood lipid levels and process therefor |
| JPS62236469A (en) | 1986-04-04 | 1987-10-16 | Yasutake Hichi | Low-calorie food and drink |
| US5266560A (en) * | 1988-06-03 | 1993-11-30 | Thomas Research Corporation | Pharmaceutical insulin-potentiating CR(III) complexes with GTF-like activity |
| US5543405A (en) | 1993-10-22 | 1996-08-06 | Keown; Wendy J. | Composition and method for weight reduction and long term management of obesity |
| US5480657A (en) | 1993-10-27 | 1996-01-02 | Allen; Ann De Wees T. | Composition comprising caffeine chromium and fructose for weight control and use thereof |
| US5612039A (en) | 1994-03-14 | 1997-03-18 | Nini E. Policappelli | Dietary supplement |
| US5567424A (en) | 1994-06-10 | 1996-10-22 | Reliv International, Inc. | Fiber, antioxidant, herbal and enzyme supplemented beverage composition for human consumption |
| US6352713B1 (en) | 1999-12-01 | 2002-03-05 | Drugtech Corporation | Nutritional composition |
| US5536516A (en) | 1994-08-24 | 1996-07-16 | Renaissance Herbs, Inc. | Hydroxycitric acid concentrate and food products prepared therefrom |
| US20040196181A1 (en) * | 1994-09-22 | 2004-10-07 | Huston Charles D. | Method and apparatus for message display on a golf course |
| EP0714663A3 (en) | 1994-11-28 | 1997-01-15 | Lilly Co Eli | Potentiation of a drug by a serotonin 1A receptor antagonist |
| AU5736096A (en) | 1995-05-15 | 1996-11-29 | Sabinsa Corporation | A new process for the production of potassium hydroxy citric acid, and compositions containing the potassium hydroxy cit ric acid |
| US5626849A (en) | 1995-06-07 | 1997-05-06 | Reliv International, Inc. | Weight loss composition for burning and reducing synthesis of fats |
| IT1276253B1 (en) | 1995-12-15 | 1997-10-27 | Sigma Tau Ind Farmaceuti | PHARMACEUTICAL COMPOSITION CONTAINING L-CARNITINE OR ALCANOIL L-CARNITINE FOR THE PREVENTION AND TREATMENT OF SOFT STATES |
| US5716976A (en) | 1996-03-13 | 1998-02-10 | Bernstein; Richard K. | Method of treatment for carbohydrate addiction |
| FI120290B (en) | 1996-12-30 | 2009-09-15 | Mirador Res Oy Ltd | Process by which such herbal, food component and food compositions can be made which reduce serum cholesterol |
| AU6141498A (en) | 1997-02-04 | 1998-08-25 | John V. Kosbab | Compositions and methods for prevention and treatment of vascular degenerative diseases |
| US5962030A (en) | 1997-03-07 | 1999-10-05 | Akesis Pharmaceuticals, Inc. | Dietary supplement and method of treatment for diabetic control |
| JP3736776B2 (en) | 1997-03-25 | 2006-01-18 | 宝ホールディングス株式会社 | New calcium composition |
| US5981510A (en) | 1997-04-15 | 1999-11-09 | Yaizu Suisankagaku Industry Co., Ltd. | Method for treating and improving diabetes |
| US5911992A (en) | 1997-06-12 | 1999-06-15 | A. Glenn Braswell | Method for controlling weight with hypericum perforatum and garcinia cambogia |
| WO1999003464A1 (en) | 1997-07-14 | 1999-01-28 | Interhealth Nutraceuticals Incorporated | Hydroxycitric acid compositions, pharmaceutical and dietary supplements and food products made therefrom, and methods for their use in reducing body weight |
| US5877171A (en) | 1997-07-28 | 1999-03-02 | Mcleod; Malcolm N. | Method of treating pre-menstrual syndrome using chromium |
| US6160172A (en) | 1997-08-27 | 2000-12-12 | Vittal Mallya Scientific Research Foundation | Soluble double metal salt of group IA and IIA of (-) hydroxycitric acid, process of preparing the same and its use in beverages and other food products without effecting their flavor and properties |
| CA2320368C (en) | 1998-02-23 | 2007-08-21 | Taiyo Kagaku Co., Ltd. | Composition comprising theanine |
| US6048846A (en) | 1998-02-26 | 2000-04-11 | Cochran; Timothy M. | Compositions used in human treatment |
| US6258848B1 (en) | 1998-07-31 | 2001-07-10 | Mount Sinai Hospital | Methods and compositions for increasing insulin sensitivity |
| US5905075A (en) | 1998-08-28 | 1999-05-18 | Ambi Inc. | Chromium nicotinate compositions and uses thereof |
| AU5802499A (en) | 1998-09-01 | 2000-03-21 | Amway Corporation | Diet composition and method of weight management |
| CA2364245C (en) | 1999-02-18 | 2010-10-05 | Vittal Mallya Scientific Research Foundation | Water soluble group ia and iia double metal salt of(-)- hydroxycitric acid |
| WO2000057729A2 (en) | 1999-03-26 | 2000-10-05 | Akesis Pharmaceuticals, Inc. | Beverages for treatment of glucose metabolism disorders |
| US6207714B1 (en) * | 1999-09-14 | 2001-03-27 | Dallas L. Clouatre | Methods and pharmaceutical preparations for improving glucose metabolism with (−)-hydroxycitric acid |
| US6447807B1 (en) | 1999-09-14 | 2002-09-10 | Dallas L. Clouatre | Potassium (-)-hydroxycitric acid methods for pharmaceutical preparations for stable and controlled delivery |
| US20030220329A1 (en) | 1999-09-17 | 2003-11-27 | Duke University | Method of improving beta-adrenergic receptor function |
| IL149907A0 (en) | 1999-12-16 | 2002-11-10 | Mark Nutritionals Inc | Nutritional composition, methods of producing said composition and methods of using said composition |
| US6291533B1 (en) | 1999-12-22 | 2001-09-18 | Vitamerica, Inc. | Dietary supplements for each specific blood type |
| US7015250B2 (en) | 2000-02-09 | 2006-03-21 | Glykon Technologies Group, Llc | Methods and pharmaceutical preparations for normalizing blood pressure with (-)-hydroxycitric acid |
| US6399089B1 (en) | 2000-05-15 | 2002-06-04 | A. Glenn Braswell | Compositions and methods for regulating metabolism and balancing body weight |
| US6383482B1 (en) | 2000-08-24 | 2002-05-07 | Vitacost.Com, Inc. | Weight loss composition containing green tea, hydroxycitric acid, 5-hydroxytryptophan, glucomannan, picolinate and lactobacillus |
| AU2001294602A1 (en) * | 2000-09-21 | 2002-04-02 | Nutrition 21, Inc. | Chromium containing compositions for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity and reduction of hyperglycemia and hypercholesteremia |
| US6579866B2 (en) | 2000-12-28 | 2003-06-17 | Mccleary Larry | Composition and method for modulating nutrient partitioning |
| US6420350B1 (en) | 2001-01-18 | 2002-07-16 | Goen Group, Inc. | Weight loss product |
| NZ528681A (en) | 2001-03-30 | 2005-03-24 | Interhealth Nutraceuticals Inc | Compositions comprising (-)-hydroxycitric acid (HCA), chromium and gymnemic acid to increase serotonin levels and induce weight loss |
| US20040157929A1 (en) | 2002-04-01 | 2004-08-12 | Ohia Sunny E. | Method for increasing serotonin levels in a person by administration of a composition incorporating(-)hydroxycitric acid, and related compositions thereof |
| US6476071B1 (en) | 2001-05-07 | 2002-11-05 | Dallas L. Clouatre | Correcting polymorphic metabolic dysfunction with (−)-hydroxycitric acid |
| US6441041B1 (en) | 2001-06-20 | 2002-08-27 | Dallas L. Clouatre | (-)-hydroxycitric acid for the prevention of osteoporosis |
| US6482858B1 (en) | 2001-06-20 | 2002-11-19 | Dallas L Clouatre | (−)-hydroxycitric acid for wound healing and immunomodulation |
| US6638542B2 (en) | 2001-09-20 | 2003-10-28 | Nutricia N.V. | Reducing appetite in mammals by administering procyanidin and hydroxycitric acid |
| US7119110B2 (en) | 2001-10-05 | 2006-10-10 | Interhealth Nutraceuticals Incorporated | Method and composition for preventing or reducing the symptoms of insulin resistance syndrome |
| US20030119913A1 (en) | 2001-12-20 | 2003-06-26 | Ohia Sunny E. | Method for increasing serotonin levels in a person by administration of a composition incorporating (-)-hydroxycitric acid, and related compositions thereof |
| WO2003092730A1 (en) | 2002-04-30 | 2003-11-13 | Unibar Corporation | Hydroxycitric acid salt composition and method of making |
| US6967030B2 (en) * | 2003-01-14 | 2005-11-22 | Wright Jonathan V | Formulation for insulin and glucose control |
| US20040186181A1 (en) | 2003-03-21 | 2004-09-23 | Interhealth Nutraceuticals, Incorporated | Method and composition for decreasing ghrelin levels |
-
2002
- 2002-10-04 US US10/265,093 patent/US7119110B2/en not_active Expired - Lifetime
- 2002-10-07 WO PCT/US2002/031987 patent/WO2003039535A1/en not_active Ceased
- 2002-10-07 IL IL16118602A patent/IL161186A0/en unknown
- 2002-10-07 EP EP02786372A patent/EP1438038A4/en not_active Withdrawn
- 2002-10-07 AU AU2002351456A patent/AU2002351456B2/en not_active Ceased
- 2002-10-07 MX MXPA04003233A patent/MXPA04003233A/en active IP Right Grant
- 2002-10-07 JP JP2003541826A patent/JP2005508371A/en active Pending
- 2002-10-07 CA CA002462158A patent/CA2462158A1/en not_active Abandoned
-
2004
- 2004-04-06 ZA ZA200402688A patent/ZA200402688B/en unknown
- 2004-12-09 US US11/009,266 patent/US7153877B2/en not_active Expired - Lifetime
-
2005
- 2005-05-13 US US11/128,727 patent/US20050202101A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7153877B2 (en) | Method and composition for preventing or reducing the symptoms of insulin resistance syndrome | |
| AU2002351456A1 (en) | Method and composition for preventing or reducing the symptoms of insulin resistance syndrome | |
| US10583168B1 (en) | Nutritional supplements including cardiovascular support components | |
| AU2002211452B2 (en) | Compositions and methods for lowering plasma lipoprotein(a) and risk factors of cardiovascular diseases | |
| Vasques et al. | Evaluation of the pharmacotherapeutic efficacy of Garcinia cambogia plus Amorphophallus konjac for the treatment of obesity | |
| US7335651B2 (en) | Compositions incorporating(-)-hydroxycitric acid and related methods for promoting fat oxidation | |
| US6203819B1 (en) | Dietary supplement and method of treatment for diabetic control | |
| US20050214384A1 (en) | Chromium compositions and methods for using the same for inhibiting drug-induced insulin resistance | |
| PT1397148E (en) | Chromium/biotin treatment of dyslipidemia | |
| US20040186181A1 (en) | Method and composition for decreasing ghrelin levels | |
| US20160220581A1 (en) | Chromium compositions for the treatment or prevention of diabetic retinopathy | |
| US20030039708A1 (en) | Non-ma huang herb weight loss product | |
| JPH05336923A (en) | Use of product containing chromium, vitamin e and vitamin c for controlling metabolism of carbohydrate and lipid | |
| Katholi et al. | Metabolic and Renal Protective Benefits of Magnesium Supplementation in the Long-Term Management of Patients with Type 2 Diabetes Mellitus | |
| US20070072910A1 (en) | Compositions and methods for lowering plasma concentrations of low density lipoproteins in humans | |
| Marrapodi | Dangerous Synergy | |
| AU2007202775A1 (en) | Compositions incorporating (-)- hydroxycitric acid, chromium, and gymnemic acid, and related methods for promoting healthy body weight and improving related health factors | |
| KUPECZ | Metformin: An Antihyperglycemic Drug for Non–Insulin-Dependent Diabetes Mellitus | |
| CAPSULES | A FLOOD OF | |
| Stott | The role of HDL-C in diabetes and the metabolic syndrome |